zintick

Aquestive Therapeutics AQST

Aquestive Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations

$4.04-4.49%close on Oct. 29, 2026 · volume 2.0M · Yahoo Finance

Price, last 48 sessions

$4.00$4.50$5.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 29, 2026 · high $5.39 · low $3.78 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Oct. 15, 2026Daniel Barber
President and CEO, director
Sold
10b5-1 plan
25,000$4.22$105,600
Sept. 15, 2026Daniel Barber
President and CEO, director
Sold
10b5-1 plan
25,000$4.82$120,487
Sept. 9, 2026Sherry Korczynski
Chief Commercial Officer
Sold
10b5-1 plan
8,750$5.22$45,675
Aug. 17, 2026Daniel Barber
President and CEO, director
Sold
10b5-1 plan
25,000$4.29$107,168

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 21 →
  • 4Oct. 23, 2026, 1:38 p.m. ETView on SEC.gov
  • 8-KOct. 19, 2026, 4:04 p.m. ETView on SEC.gov

    Amendments to articles or bylaws; fiscal year change · Financial statements and exhibits

    AI summary, unreviewedAquestive Therapeutics Amends Bylaws to Remove Concert-Action Nomination Disclosure Requirements; No Financial Impact Disclosed

  • 4Oct. 16, 2026, 2:17 p.m. ETView on SEC.gov
  • 8-KOct. 15, 2026, 7:21 a.m. ETView on SEC.gov

    Regulation FD disclosure · Financial statements and exhibits

    AI summary, unreviewedAquestive Therapeutics Gets FDA Acceptance of Anaphylm NDA Resubmission, PDUFA Date Set for March 16, 2027

  • 8-KOct. 14, 2026, 7:21 a.m. ETView on SEC.gov

    Entry into a material definitive agreement · Financial statements and exhibits

  • SCHEDULE 13GOct. 7, 2026, 3:47 p.m. ETView on SEC.gov
  • SCHEDULE 13G/AOct. 7, 2026, 2:14 p.m. ETView on SEC.gov
  • 8-KSept. 29, 2026, 7:22 a.m. ETView on SEC.gov

    Departure/appointment of directors or officers · Financial statements and exhibits